Spinal Cord Injury Pipeline Analysis, Clinical Trials, 2025 By Delveinsight EUSOL Biotech, Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, Nervgen Pharma, Alamab The

(MENAFN- GetNews)


"Spinal Cord Injury Pipeline Analysis"DelveInsight's,“Spinal Cord Injury - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Spinal Cord Injury pipeline features over 25 leading companies actively developing more than 30 therapies for the treatment of spinal cord injury.

DelveInsight's "Spinal Cord Injury – Pipeline Insight, 2025 " offers a concise overview of the current pipeline landscape and future growth potential in spinal cord injury. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.

Key Takeaways from the Spinal Cord Injury Pipeline Report:

• DelveInsight's analysis of the spinal cord injury (SCI) pipeline reveals a dynamic landscape, with over 25 active companies developing more than 30 investigational therapies across various stages of clinical development.

• In December 2024, the U.S. Food and Drug Administration (FDA) granted de novo classification and market approval to ONWARD Medical's ARC-EX system. This non-invasive spinal cord stimulation device is the first approved to enhance hand strength and sensation in individuals with chronic SCI, with clinical trials showing that 72% of participants experienced improved hand function and sensory perception.

• In May 2024, the FDA approved Abbott's range of Spinal Cord Stimulation (SCS) systems-including Prodigy, Proclaim Plus, Proclaim XR, and Eterna-implantable neurostimulators designed to alleviate chronic pain in the torso, arms, and legs, providing relief for patients with otherwise intractable pain conditions.

• Leading companies such as EUSOL Biotech Co., Ltd., Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, NervGen Pharma, AlaMab Therapeutics, Axonis Therapeutics, NurExone Biologic, and others are actively developing novel drugs to advance SCI treatment options.

• Notable pipeline candidates under investigation include ES-1601, MT-3921, NVG-291, among others, highlighting the promise of emerging therapies across different stages of development.

Spinal Cord Injury Overview

A spinal cord injury (SCI) refers to trauma-induced damage to the spinal cord or the nerve roots at the base of the spinal canal. This disruption interferes with the transmission of motor and sensory signals across the affected area. SCI is a disabling neurological condition with significant personal, psychological, and economic consequences, impacting both individuals and the healthcare system.

Spinal cord injuries are categorized as either complete or incomplete. A complete injury leads to a total loss of sensory and motor function below the site of the injury, whereas an incomplete injury allows for partial retention of function.

SCI can lead to either temporary or permanent loss of movement, sensation, or autonomic control below the site of damage. The extent of the impairment varies based on the location and severity of the injury. Common symptoms include paralysis (either quadriplegia or paraplegia), sensory deficits, bladder and bowel dysfunction, and issues with autonomic regulation such as unstable blood pressure. Injuries to the upper cervical spine can compromise respiratory function, making prompt medical care critical.

Overall, SCI profoundly affects a person's physical capabilities and quality of life, often requiring long-term medical, psychological, and social support.

Uncover the latest breakthroughs in SCI therapeutics, download our spinal cord injury market report

Spinal Cord Injury Pipeline Analysis

The Spinal Cord Injury pipeline insights report 2025 provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Spinal Cord Injury Market.

• Categorizes Spinal Cord Injury therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Spinal Cord Injury drugs under development based on:

  • Stage of development

  • Spinal Cord Injury Route of Administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Spinal Cord Injury Mechanism of Action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Spinal Cord Injury Licensing Agreements

  • Funding and investment activities that support future advancements in the Spinal Cord Injury market.

Get Full Insights into the Spinal Cord Injury Pipeline and Future Market Trends – Download the Report Now:

Spinal Cord Injury Emerging Drugs

• ES-1601: EUSOL Biotech Co., Ltd.

• MT-3921: Mitsubishi Tanabe Pharma Corporation

• NVG-291: NervGen

Spinal Cord Injury Pipeline Therapeutic Assessment

Spinal Cord Injury Assessment by Product Type

. Mono

. Combination

. Mono/Combination

Spinal Cord Injury By Stage

. Late-stage products (Phase III)

. Mid-stage products (Phase II)

. Early-stage product (Phase I) along with the details of

. Pre-clinical and Discovery stage candidates

. Discontinued & Inactive candidates

Spinal Cord Injury Assessment by Route of Administration

. Intravenous

. Subcutaneous

. Oral

. Intramuscular

Spinal Cord Injury Assessment by Molecule Type

. Monoclonal antibody

. Small molecule

. Peptide

Download the Spinal Cord Injury Sample Report for Key Insights on the Spinal Cord Injury Treatment Market and Therapeutics

Table of Contents

1. Report Introduction

2. Executive Summary

3. Spinal Cord Injury Current Treatment Patterns

4. Spinal Cord Injury - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Spinal Cord Injury Late-Stage Products (Phase-III)

7. Spinal Cord Injury Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Spinal Cord Injury Discontinued Products

13. Spinal Cord Injury Product Profiles

14. Spinal Cord Injury Key Companies

15. Spinal Cord Injury Key Products

16. Dormant and Discontinued Products

17. Spinal Cord Injury Unmet Needs

18. Spinal Cord Injury Future Perspectives

19. Spinal Cord Injury Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Spinal Cord Injury Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN02092025003238003268ID1110008894